Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 12;41(9):1296–1306. doi: 10.1038/s41587-022-01626-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 3 — a, Cytokine production in cynomolgus monkeys treated with the high and low doses of 3 mg/kg and 3 µg/kg as single 1-hour intravenous infusion, respectively. Plasma IL-10 concentrations are shown before dosing (0), and 1.5, 5 and 24 hours after the start of the treatment. b, Numbers of circulating CD123-positive basophils (close symbols) and total CD123-positive leukocytes (open symbols) at time of study in monkeys M6 (pink) and M3 (black) treated with 0.5 and 3 µg/kg as single 1-hour intravenous infusion, respectively. c, Pharmacokinetics of the CD123-NKCE molecule in monkeys M1 (orange) and M2 (purple) treated with 3 mg/kg (left panel), and monkeys M3 (black) and M4 (blue) treated with 3 µg/kg (right panel). Plasma CD123-NKCE concentrations were monitored 1.5, 5, 24, 48, 72, 168, 240, 336, 504 and 672 hours (that is 0.04, 0.06, 0.21, 1, 2, 3, 7, 10, 14, 21 and 28 days) after the start of the one-hour infusion. The lower limit of quantification (LLOQ; 0.25 ng/mL) is indicated by the horizontal dotted line. d, Individual Anti-Drug antibody (ADA) ratio of monkeys M1 (orange) and M2 (purple) treated with 3 mg/kg, and monkeys M3 (black) and M4 (blue) treated with 3 µg/kg. Presence of ADA in plasma was monitored at predose (baseline) and at day 1, 7, 10, and 28 after the start of the one-hour infusion.